Another interesting look into the PPAR agonist (like cardarine) & AMPk activator (like metformin) synergy for fat loss purposes.
The short:
They have a strong synergy for increasing endurance, not to mention the secondary effects useful to a physique athlete with each individual compound, most notably with nutrient partitioning. (Such as improving insulin sensitivity with metformin, and increasing muscle cell glucose uptake with GW)
The long:
- AMP-mimetic AICAR can increase endurance in*sedentary mice by genetically reprogramming muscle metabolism
- PPARδ agonists in combination with exercise synergistically induces fatigue-resistant type I fiber specification and mitochondrial biogenesis, ultimately enhancing physical performance.
- The synergy resulted in a unique muscle endurance gene signature.
- GW1516 and AICAR synergistically induced several endurance-related genes
- treatment of animals with AICAR and GW1516 creates a gene signature in skeletal muscle that replicates up to 40% of the genetic effects of combined exercise and GW1516 treatment
- the shared genes between the two profiles are linked to oxidative metabolism, angiogenesis, and glucose sparing pathways that are directly relevant to muscle performance
- synthetic PPARδ activation and AMPK activation alone provides a transcriptional cue that reprograms the skeletal muscle genome and dramatically enhances endurance.
http://www.cell.com/cell/fulltext/S...m/retrieve/pii/S0092867408008386?showall=true
Sent from my iPhone using Tapatalk
